2026 Global: Drug Device Combination Products-Competitive Review (2032) report
Description
The 2026 Global: Drug Device Combination Products-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Johnson & Johnson, headquartered in New Brunswick, United States, is a health care company with a track record in drug-device combination products, including auto-injector platforms, prefilled syringes, and interventional devices that couple therapeutic agents with delivery devices and hardware. Medtronic, based in Dublin, Ireland, is a technology leader whose portfolio encompasses infusion pumps, drug-coated delivery systems, and cardiovascular devices that merge therapy with implanted hardware to improve outcomes. Abbott, headquartered in Abbott Park, United States, maintains a broad portfolio bridging pharmaceuticals and devices, notably insulin delivery devices and other combination platforms that streamline administration and adherence. Becton, Dickinson and Company, headquartered in Franklin Lakes, United States, supplies injection and infusion components as well as drug-delivery platforms, enabling integrated therapies across hospital, clinic, and home settings. The common thread among these companies is the strategic integration of a drug with a device to improve delivery, dosing accuracy, safety, and patient convenience.
Novo Nordisk, based in Bagsværd, Denmark, is a leading producer of diabetes therapies that extensively uses injection devices and reusable pens designed to deliver precise dosages, turning pharmacotherapy into user-friendly drug-device combinations. Sanofi, headquartered in Paris, France, leverages its portfolio of biologics, insulins, and inhalation therapies with integrated devices that enhance adherence and dosing accuracy in chronic diseases. Merck & Co., headquartered in Kenilworth, United States, develops combination products through auto-injector systems, prefilled syringes, and companion devices that facilitate self-administration and remote monitoring of therapies. Pfizer, based in New York, United States, also delivers a range of combination products, including autoinjectors and smart delivery platforms that integrate drug formulations with delivery hardware to improve administration convenience and patient safety. Across these portfolios, collaboration with device partners, regulatory navigation, and patient-centric design drive development timelines and safety improvements in drug-device combinations. Real-world data and post-market surveillance further refine delivery methods globally.
Bayer, headquartered in Leverkusen, Germany, operates as a global life sciences company with a broad pharmaceutical portfolio and a growing presence in device-assisted therapies, including drug-coated balloons and combination delivery systems designed to treat vascular disease more effectively. Boston Scientific, headquartered in Marlborough, United States, is a leading medical device company with extensive experience in drug-eluting stents and other combination products that couple pharmacologic agents with supportive hardware to restore and maintain perfusion. The increasing prominence of drug-device combinations across these firms reflects a broader industry trend toward integrated therapies that improve local drug delivery, minimize systemic exposure, and support patient adherence through convenient, user-friendly platforms. These developments also stimulate collaboration with regulatory agencies to establish robust safety and efficacy evidence, while manufacturing integration, supply chain reliability, and scale-up capabilities ensure that innovative drug-device combinations reach markets promptly and equitably. Public-private partnerships will accelerate adoption and ensure affordability for patients.
Johnson & Johnson, headquartered in New Brunswick, United States, is a health care company with a track record in drug-device combination products, including auto-injector platforms, prefilled syringes, and interventional devices that couple therapeutic agents with delivery devices and hardware. Medtronic, based in Dublin, Ireland, is a technology leader whose portfolio encompasses infusion pumps, drug-coated delivery systems, and cardiovascular devices that merge therapy with implanted hardware to improve outcomes. Abbott, headquartered in Abbott Park, United States, maintains a broad portfolio bridging pharmaceuticals and devices, notably insulin delivery devices and other combination platforms that streamline administration and adherence. Becton, Dickinson and Company, headquartered in Franklin Lakes, United States, supplies injection and infusion components as well as drug-delivery platforms, enabling integrated therapies across hospital, clinic, and home settings. The common thread among these companies is the strategic integration of a drug with a device to improve delivery, dosing accuracy, safety, and patient convenience.
Novo Nordisk, based in Bagsværd, Denmark, is a leading producer of diabetes therapies that extensively uses injection devices and reusable pens designed to deliver precise dosages, turning pharmacotherapy into user-friendly drug-device combinations. Sanofi, headquartered in Paris, France, leverages its portfolio of biologics, insulins, and inhalation therapies with integrated devices that enhance adherence and dosing accuracy in chronic diseases. Merck & Co., headquartered in Kenilworth, United States, develops combination products through auto-injector systems, prefilled syringes, and companion devices that facilitate self-administration and remote monitoring of therapies. Pfizer, based in New York, United States, also delivers a range of combination products, including autoinjectors and smart delivery platforms that integrate drug formulations with delivery hardware to improve administration convenience and patient safety. Across these portfolios, collaboration with device partners, regulatory navigation, and patient-centric design drive development timelines and safety improvements in drug-device combinations. Real-world data and post-market surveillance further refine delivery methods globally.
Bayer, headquartered in Leverkusen, Germany, operates as a global life sciences company with a broad pharmaceutical portfolio and a growing presence in device-assisted therapies, including drug-coated balloons and combination delivery systems designed to treat vascular disease more effectively. Boston Scientific, headquartered in Marlborough, United States, is a leading medical device company with extensive experience in drug-eluting stents and other combination products that couple pharmacologic agents with supportive hardware to restore and maintain perfusion. The increasing prominence of drug-device combinations across these firms reflects a broader industry trend toward integrated therapies that improve local drug delivery, minimize systemic exposure, and support patient adherence through convenient, user-friendly platforms. These developments also stimulate collaboration with regulatory agencies to establish robust safety and efficacy evidence, while manufacturing integration, supply chain reliability, and scale-up capabilities ensure that innovative drug-device combinations reach markets promptly and equitably. Public-private partnerships will accelerate adoption and ensure affordability for patients.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
